新型HBV血清学标志物的潜在临床价值

Potential clinical value of new type of HBV serological markers ranking in the review column

在我国,慢性乙型肝炎(CHB)及其所导致的纤维化、肝硬化和肝细胞癌仍是严重影响人群健康的重大疾病。很多患者经治疗虽然检测不到血清HBV DNA,但也会出现肝脏疾病的进展,因此,应该寻找除HBV DNA、HBsAg定量之外的新型血清学标志物,有利于CHB抗病毒药物及方式的选择、疗效监测随访、疗效预测以及预测停药后病毒学反弹风险等。现重点阐述HBV核心相关抗原、HBV RNA、抗-HBc这三种新型有望应用于临床实践的血清学标志物。

Liver fibrosis,liver cirrhosis and hepatocellular carcinoma caused by chronic hepatitis B are still the main diseases that seriously affect the health of Chinese population.Notably,even if serum HBV-DNA cannot be detected after treatment,many patients will still develop liver disease.Therefore,in addition to the quantitative analysis of HBV-DNA and HBsAg,other new serological markers should be sought to facilitate the selection of CHB antiviral drugs and methods,monitoring efficacy and follow-up,efficacy prediction,and the risks of viral rebound after drug withdrawal.This article focuses on three new serological markers,namely HBcrAg,HBV-RNA and anti-HBc,with a view to applying them in clinical practice.